Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.
Moya B, Barcelo IM, Cabot G, Torrens G, Palwe S, Joshi P, Umarkar K, Takalkar S, Periasamy H, Bhagwat S, Patel M, Bou G, Oliver A. Moya B, et al. Among authors: periasamy h. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e00128-19. doi: 10.1128/AAC.00128-19. Print 2019 May. Antimicrob Agents Chemother. 2019. PMID: 30782985 Free PMC article.
Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.
Bhagwat SS, Nandanwar M, Kansagara A, Patel A, Takalkar S, Chavan R, Periasamy H, Yeole R, Deshpande PK, Bhavsar S, Bhatia A, Ahdal J, Jain R, Patel M. Bhagwat SS, et al. Among authors: periasamy h. Drug Des Devel Ther. 2019 Dec 24;13:4351-4365. doi: 10.2147/DDDT.S229882. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31920285 Free PMC article. Review.
Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study.
Bhatia A, Mastim M, Shah M, Gutte R, Joshi P, Kumbhar D, Periasamy H, Palwe SR, Chavan R, Bhagwat S, Patel M, Llorens L, Friedland HD. Bhatia A, et al. Among authors: periasamy h. J Assoc Physicians India. 2020 Aug;68(8):30-36. J Assoc Physicians India. 2020. PMID: 32738837 Clinical Trial.
In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
Bhagwat SS, Legakis NJ, Skalidis T, Loannidis A, Goumenopoulos C, Joshi PR, Shrivastava R, Palwe SR, Periasamy H, Patel MV, Chatzipanagiotou S; Hellenic Cefepime/Zidebactam Study Group. Bhagwat SS, et al. Among authors: periasamy h. Diagn Microbiol Infect Dis. 2021 Jul;100(3):115327. doi: 10.1016/j.diagmicrobio.2021.115327. Epub 2021 Jan 30. Diagn Microbiol Infect Dis. 2021. PMID: 33744624
In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy.
Barceló I, Cabot G, Palwe S, Joshi P, Takalkar S, Periasamy H, Cortés-Lara S, Zamorano L, Sánchez-Diener I, Moya B, Bhagwat S, Patel M, Oliver A. Barceló I, et al. Among authors: periasamy h. J Antimicrob Chemother. 2021 Sep 15;76(10):2546-2557. doi: 10.1093/jac/dkab213. J Antimicrob Chemother. 2021. PMID: 34219168
17 results